· Princeton Facility Designated as New Headquarters· Regional Multi-Site Operations to Advance Clinical-to-Commercial Capabilities· $12M Capital Investment for State-of-the-Art Operations and Digital Advancements Newark, NJ, December 17, 2024 – BioCentriq, a leading cell therapy contract …
Read more
Newark, NJ, September 19, 2024 – BioCentriq, a leading cell therapy contract development and manufacturing organization (CDMO), today announces that it has appointed Syed T. Husain as its new Chief Executive Officer (CEO), and as …
Read more
Watch Chathuranga De Silva, Ph.D., Executive Director, Business Development at BioCentriq in an engaging interview with Alicia Didsbury during the ISCT 2024 Annual Meeting in Vancouver. In this interview, Chat highlights BioCentriq’s unwavering commitment to …
Read more
In June, BioCentriq hosted a webinar called End-to-End Automated Manufacturing of Low-Seed CAR-T Cells where we explored the intricate pathway to achieving commercial readiness in CAR-T cell therapy. In this session, we address crucial aspects …
Read more
Explore BioCentriq’s capabilities and expertise presented by Chathuranga De Silva, Ph.D., Executive Director of Business Development at BioCentriq. In this session, recorded during Outsourced Pharma’s Cell & Gene Capacity Update July 2024, Chat delivers an …
Read more
Welcome to Biotech Banter, where we bring you exclusive insights from top experts in the biotech industry. Our thought leaders and seasoned professionals explore the challenges and opportunities of advancing cell and gene therapies to …
Read more